...
首页> 外文期刊>Journal of Cancer Research and Therapeutics >A study on the impact of patient-related parameters in the ability to spare parotid glands by intensity-modulated radiotherapy for head and neck squamous cell carcinomas
【24h】

A study on the impact of patient-related parameters in the ability to spare parotid glands by intensity-modulated radiotherapy for head and neck squamous cell carcinomas

机译:患者相关参数对头颈部鳞状细胞癌强度调制放疗对腮腺备用能力的影响

获取原文
           

摘要

Aims and Objectives: This study aims to study the effect of geometric- and patient-related variables in achieving the desired dose-volume constraints to parotid for patients undergoing definitive/adjuvant intensity-modulated radiotherapy (IMRT) for head and neck squamous cell carcinomas (HNSCC). Subjects and Methods: This retrospective study considered HNSCC patients who underwent IMRT at our center between 2009 and 2014. Patients' details and dose-volume parameters were collected, and correlated with dose to parotids using Pearson's correlation test. Results: Sixty-seven patients were found to be eligible. Oral primary predominated (37.3%) and 53 (79%) had locally advanced disease. The parotid volume (PV) had no impact on mean dose. There was a negative linear correlation between the ratio (Parotid-planning target volume [PTV] overlap)/PV and mean dose to the whole parotid (y = 1.14-0.011×; R2 = 0.509; P = 0.001), suggesting that a ratio of 0.7 resulted in mean dose ≥ 40 Gy and potentially irreversible xerostomia. No association was found between site of primary and parotid dose, but node-positive (N+) patients received significantly higher dose compared to N0 patients (34.5 Gy vs. 29.5 Gy; P = 0.001). N + patients persisted to receive higher dose even when T stage was accounted for (32.5 Gy vs. 28.9 Gy for T2; P = 0.003). On the last follow-up, 35 patients (52%) had /=Grade II xerostomia. Average mean dose to combined PV was higher in patients with grade I xerostomia compared to patients with P = 0.01). Conclusion: The degree of PTV overlap with parotid (≥30%) and N + disease are the strongest predictors of poor parotid sparing by IMRT.
机译:目的和目的:本研究旨在研究几何和患者相关变量对头颈部鳞状细胞癌行定性/辅助强度调制放射治疗(IMRT)的患者达到期望的腮腺剂量限制的作用( HNSCC)。受试者与方法:这项回顾性研究纳入了2009年至2014年在我们中心接受IMRT的HNSCC患者。收集了患者的详细信息和剂量-体积参数,并使用Pearson相关检验将其与腮腺的剂量相关联。结果:67名患者符合条件。口服原发性占主导地位(37.3%),有53例(79%)患有局部晚期疾病。腮腺体积(PV)对平均剂量没有影响。比例(靶计划目​​标体积[PTV]重叠)/ PV与整个腮腺的平均剂量之间存在线性负相关(y = 1.14-0.011×; R2 = 0.509; P = 0.001),表明该比例0.7导致平均剂量≥40 Gy,并可能导致不可逆的口干症。在初次和腮腺给药部位之间未发现关联,但是淋巴结阳性(N +)患者的剂量明显高于N0患者(34.5 Gy对29.5 Gy; P = 0.001)。即使考虑了T期,N +患者仍坚持接受更高剂量(T2为32.5 Gy对28.9 Gy; P = 0.003)。在最后一次随访中,有35名患者(52%)≥II级口干症。 I级口腔干燥症患者的合并PV的平均平均剂量高于P = 0.01的患者。结论:PTV与腮腺重叠的程度(≥30%)和N +疾病是IMRT腮腺保留不良的最强预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号